Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV)

Tipranks - Tipranks - Sat Mar 21, 5:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) with bullish sentiments.

Claim 70% Off TipRanks Premium

4D Molecular Therapeutics (FDMT)

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $36.00. The company’s shares closed last Thursday at $8.98.

According to TipRanks.com, Caufield is a 5-star analyst with an average return of 17.5% and a 44.8% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Phathom Pharmaceuticals, and Tarsus Pharmaceuticals. ;'>

Currently, the analyst consensus on 4D Molecular Therapeutics is a Moderate Buy with an average price target of $32.20, implying a 223.9% upside from current levels. In a report issued on March 18, Chardan Capital also maintained a Buy rating on the stock with a $26.00 price target.

See the top stocks recommended by analysts >>

Scholar Rock Holding (SRRK)

Cantor Fitzgerald analyst Eric Schmidt FCA maintained a Buy rating on Scholar Rock Holding yesterday. The company’s shares closed last Thursday at $45.50, close to its 52-week high of $46.98.

According to TipRanks.com, FCA is ranked #297 out of 12128 analysts.

Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $56.50, implying a 44.3% upside from current levels. In a report issued on March 5, TipRanks – Google also upgraded the stock to Buy with a $53.00 price target.

Acrivon Therapeutics, Inc. (ACRV)

In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Acrivon Therapeutics, Inc., with a price target of $19.00. The company’s shares closed last Thursday at $1.70.

According to TipRanks.com, Bodnar is a 4-star analyst with an average return of 5.6% and a 33.7% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Olema Pharmaceuticals, and Context Therapeutics. ;'>

Currently, the analyst consensus on Acrivon Therapeutics, Inc. is a Moderate Buy with an average price target of $13.50.

Read More on FDMT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).